Literature DB >> 34546931

New Insights Into Drug Repurposing for COVID-19 Using Deep Learning.

Chun Yen Lee, Yi-Ping Phoebe Chen.   

Abstract

The coronavirus disease 2019 (COVID-19) has continued to spread worldwide since late 2019. To expedite the process of providing treatment to those who have contracted the disease and to ensure the accessibility of effective drugs, numerous strategies have been implemented to find potential anti-COVID-19 drugs in a short span of time. Motivated by this critical global challenge, in this review, we detail approaches that have been used for drug repurposing for COVID-19 and suggest improvements to the existing deep learning (DL) approach to identify and repurpose drugs to treat this complex disease. By optimizing hyperparameter settings, deploying suitable activation functions, and designing optimization algorithms, the improved DL approach will be able to perform feature extraction from quality big data, turning the traditional DL approach, referred to as a "black box," which generalizes and learns the transmitted data, into a "glass box" that will have the interpretability of its rationale while maintaining a high level of prediction accuracy. When adopted for drug repurposing for COVID-19, this improved approach will create a new generation of DL approaches that can establish a cause and effect relationship as to why the repurposed drugs are suitable for treating COVID-19. Its ability can also be extended to repurpose drugs for other complex diseases, develop appropriate treatment strategies for new diseases, and provide precision medical treatment to patients, thus paving the way to discover new drugs that can potentially be effective for treating COVID-19.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34546931      PMCID: PMC8843052          DOI: 10.1109/TNNLS.2021.3111745

Source DB:  PubMed          Journal:  IEEE Trans Neural Netw Learn Syst        ISSN: 2162-237X            Impact factor:   10.451


  60 in total

1.  deepDR: a network-based deep learning approach to in silico drug repositioning.

Authors:  Xiangxiang Zeng; Siyi Zhu; Xiangrong Liu; Yadi Zhou; Ruth Nussinov; Feixiong Cheng
Journal:  Bioinformatics       Date:  2019-12-15       Impact factor: 6.937

2.  DeepSynergy: predicting anti-cancer drug synergy with Deep Learning.

Authors:  Kristina Preuer; Richard P I Lewis; Sepp Hochreiter; Andreas Bender; Krishna C Bulusu; Günter Klambauer
Journal:  Bioinformatics       Date:  2018-05-01       Impact factor: 6.937

3.  Repurposing chlorpromazine to treat COVID-19: The reCoVery study.

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-05-16       Impact factor: 1.291

4.  Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking.

Authors:  Sovesh Mohapatra; Prathul Nath; Manisha Chatterjee; Neeladrisingha Das; Deepjyoti Kalita; Partha Roy; Soumitra Satapathi
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

5.  Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.

Authors:  Lifeng Fu; Fei Ye; Yong Feng; Feng Yu; Qisheng Wang; Yan Wu; Cheng Zhao; Huan Sun; Baoying Huang; Peihua Niu; Hao Song; Yi Shi; Xuebing Li; Wenjie Tan; Jianxun Qi; George Fu Gao
Journal:  Nat Commun       Date:  2020-09-04       Impact factor: 17.694

6.  Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning.

Authors:  Xiangxiang Zeng; Xiang Song; Tengfei Ma; Xiaoqin Pan; Yadi Zhou; Yuan Hou; Zheng Zhang; Kenli Li; George Karypis; Feixiong Cheng
Journal:  J Proteome Res       Date:  2020-07-24       Impact factor: 4.466

7.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Authors:  Christian A Devaux; Jean-Marc Rolain; Philippe Colson; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-12       Impact factor: 5.283

8.  Teicoplanin: an alternative drug for the treatment of COVID-19?

Authors:  Sophie Alexandra Baron; Christian Devaux; Philippe Colson; Didier Raoult; Jean-Marc Rolain
Journal:  Int J Antimicrob Agents       Date:  2020-03-13       Impact factor: 5.283

9.  A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.

Authors:  Donald C Hall; Hai-Feng Ji
Journal:  Travel Med Infect Dis       Date:  2020-04-12       Impact factor: 6.211

10.  Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Authors:  Fabian Sanchis-Gomar; Carl J Lavie; Daniel P Morin; Carme Perez-Quilis; Jari A Laukkanen; Marco V Perez
Journal:  Am J Cardiovasc Drugs       Date:  2020-10       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.